Severe ulcerative colitis: Present medical treatment strategies

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 3, 2008, Pages 447-457

  Baudet, Agnès ^a   Rahmi, Gabriel ^b   Bretagne, Anne Laure ^a   Gloro, Romain ^a,c   Justum, Anne Marie ^a   Reimund, Jean Marie ^a,c  

^a CHU CÔTE DE NACRE   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ DE CAEN   (France)

Author keywords

Cidosporin; Colectomy; Corticosteroids; Inflammatory bowel disease; Infliximab; Medical therapy; Severe ulcerative colitis; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN A; GANCICLOVIR; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; METRONIDAZOLE; PLACEBO; PREDNISOLONE; VANCOMYCIN; ANTIINFLAMMATORY AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COLON RADIOGRAPHY; COLON RESECTION; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; EVENING DOSAGE; FLUID THERAPY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TRACT SCINTISCANNING; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; KIDNEY FAILURE; LEGIONNAIRE DISEASE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEUROTOXICITY; OPTIMAL DRUG DOSE; PROGNOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REVIEW; THERAPY DELAY; THERAPY RESISTANCE; TOTAL PARENTERAL NUTRITION; TOXIC MEGACOLON; TREATMENT FAILURE; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS;

EID: 39049105242     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.3.447     Document Type: Review

References (98)

1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hcpatol 2006;3(7):390-407
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12(38):6102-8
3. Farrell RJ, Peppercorn MA. Ulcerative colitis. lancet 2002;359(9303):331-40
4. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125(6):1576-82
5. Card T, Hubbard R, logan RF. Mortality in inflammatory bowel disease: a population-base cohort study. Gastroenterology 2003;125(6):1583-90
6. Loftus EV Jr. Mortality in inflammatory bowel disease: peril and promise. Gastroenterology 2003;125(6):1881-3
7. Carter MJ, Lobo AJ, Travis SP. IBD Section, British Society of Gastroenterology: guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl V):V1-16
8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2(4947):1041-8
9. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004;20(Suppl 4):88-92
10. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1(7866):1067-70
11. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to intravenous steroid therapy. N Engl J Med 1994;330(26):1841-5
12. Tariverdian M, Leowardi C, Hinz U, et al. Quality of life after restorative proctocolectomy for ulcerative colitis: preoperative status and long-term results. Inflamm Bowel Dis 2007;13(10):1228-35
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76. Erratum in N Engl J Med 2006;354(20):2200
14. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128(7):1805-11
15. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27(10):1210-2
16. Kombluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology. Practice parameters committee. Am J Gastromterol 2004;99(7):1371-85
17. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy, end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132(2):763-86
18. Lichtiger S, Present DH. Preliminary report: cyclosporine in treatment of severe active ulcerative colitis (comment). lancet 1990;336(8706):16-9
19. Baumgart DC, Hommes DW, Reinisch W, et al. The Phase I-II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with IV steroids (IVSR-UC). Gut 2005;37(Suppl 1)A57 (Abstr OP-G-243)
20. Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87(8):971-6
21. Seo M, Okada M, Yao T, et al. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts classification (comments). Am J Gastroenterol 1995;90(10):1759-63
22. Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002;37(1):29-34
23. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut 1975;16(8):579-84
24. Travis SP, Farrant JM, Richetts C, et al. Predicting an outcome in severe ulcerative colitis. Gut 1996;38(6):905-10
25. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticoid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10(10):831-5
26. Caprilli R, Vernia P, Colaneri O, Torsoli A. Blood PH: a test for assessment of severity on proctocolitis. Gut 1976;17(10):763-9
27. Caprilli R, Vernia P, Colaneri O, Frieri G. Risk factors in toxic megacolon. Dig Dis Sci 1980;25(11):817-22
28. Caprilli R, Sopranzi N, Colaneri O, et al. Salt loosing diarrhea in idiopathic proctocolitis. Scand J Gastroenterol 1978;13(3):331-5
29. Caprilli R, Vernia P, Latella G, Torsoli A. Early recognition of toxic megacolon. J Clin Gastroenterol 1987;9(2):160-4
30. Chew CN, Nolan DJ, Jewel DP, Small bowel gas in severe ulcerative colitis. Gut 1991;32(12):1535-7
31. Jones JH, Chapman M. Definition of megacolon in colitis. Gut 1969;10(7):562-4
32. Latella G, Vernia P, Viscido A. et al. GI distension in severe ulcerative colitis. Am J Gastroenterol 2002;97(5):1169-75
33. Mourelle M, Casellas F, Guarner F, et al. Introduction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology 1995;109(5):1497-502
34. Onori L, Aggio, A. D'Alo'S, et al. Role of nitric oxide in the impairment of circular muscle contractility of distended, uninflamed mid-colon in TNBS-induced acute distal colitis in rats. World J Gastroenterol 2005;11(36):5677-84
35. Pullman WE, Sullivan PJ, Barran PJ, et al. Assessment of inflammatory bowel disease activity by technetium 99m phagocyte scanning. Gastroenterology 1988;95(4):989-96
36. Guimbaud R, Beades E, Chauvelot-Moachon L, et al. Technetium Tc 99m hexamethyl propylene amine oxine lcucocyte scintigraphy in patients with ulcerative colitis: correlation with clinical, biologic, endoscopic, and pathologic intensity, and local release of interleukin 8. Gastrointest Endosc 1998;48(5):491-6
37. Moreléc I, Nancey S, Roman S, et al. ls scintigraphic: double track appearance a sign of severe acute episodes of ulcerative colitis? Gastroenterol Clin Biol 2004;28(3):221-5
38. Almer S, Bodemar G, Lindstrom E, et al. Do technetium-99m h-ethylpropylene amine oxine-labelled leucocytes truly reflect the mucosal inflammation in patients with ulcerative colitis? Scand J Gastroenterol 1992;27(12):1031-8
39. Alemayehu G, Jameroth G. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastmenterol 1991;86(2):187-9
40. Carbonnel F, Lavergne A. Lemann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39(7):1550-7
41. Carbonnel F, Garoouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for severe ulcerative colitis. Aliment Pharmacol Ther 2000;14(3):273-9
42. Bouhnik Y, Alvbs A. Beau R et al. Treatment of severe ulcerative colitis. Gastroenterol Clin Biol 2004;28(10 pt 2):984-91 [article in French]
43. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):940-87
44. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5(1):103-10
45. Powell-Tuck J, Buckell NA, Lennard-Jones JE. A controlled comparison of corticotropin and hydrocortisone in the treament of severe proctocolitis. Scand J Gastroenterol 1977;12(8):971-5
46. Kaplan HP, Portnoy B, Binder HJ, Amatruda T, Spiro H. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology 1975;69(1):91-5
47. Meyers S, Sachar DB, Golberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983;85(2):351-7
48. Järnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89(5):1005-13
49. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12(1):40-1
50. Mcintyre PB, Powel-Tuck J, Wood SR. et al. Controlled trial of bowel rest in the treatment of severe ulcerative colitis. Gut 1986;27(5):481-5
51. Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79(6):1198-204
52. Dickinson RJ, O'Connor HJ, Pinder I, et al. Double-blind controlled trial of oral vancomycin as adjunctive trieatment in acute exacerbations of idiopathic colitis. Gut 1985;26(12):1380-4
53. Truelove SC. Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. lancet 1978;2(8099):1086-8
54. Mantzanaris GJ, Petraki KK, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36(9):971-4
55. Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987;9(1):504
56. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998;10(5):411-3
57. Gupta S, Keshavarzian A. Hodgson HJ. Cyclosporin in ulcerative colitis. Lancet 1984;2(8414):1277-8
58. Hyams JS, Treem. WR. Cyclosporine treatment of fulminant colitis. J Pediatr Gastroenterol Nutr 1989;9(3):383-7
59. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336(8706):16-9
60. Bianchi Porro GB, Petrillo M, Ardizzone S. Cyclosporin treatment for severe active ulcerative colitis. Lancet 1990;336(8712):439
61. Actis GC, Ottobrelli A. Pera A. et al. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colecminy in acute attacks of ulcerative colitis without the need fiir high-dose steroids. J Clin Gastroenterol 1993;17(1):10-3
62. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological cffects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6(3-4):468-75
63. 2+ signals and immunosuppression. Nature 1996;383(6603):83740
64. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann NY Acad Sci 1993;696:9-19
65. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000;47(2-3):119-25
66. Santos J, Bauder S, Cascilas F, et al. Efficacy of intravenous cyclosporine for steroid refiactory attacks of ulcerative colitis. J Clin Gastroenterol 1995;20(4):285-9
67. Treem WR, Cohen J, Davis PM, et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995;38(4):474-9
68. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999;94(6):1587-92
69. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe artacks of ulcerative colitis. Gastroenterology 2001;120(6):1323-9
70. Van Assche G, D'Haens G, Noman M, et al. Randomized double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous Cyclosporin in severe ulcerative colitis. Gastroenterology 2003;125(4):1025-31
71. Campbell S, Travis S, Jewell D. Cyclosporine use in acute ulcerative colitis: a long term experience. Eur J Gastroenterol Hepatol 2005;17(1):79-84
72. Kornbluth A, Lichtiger S, Present D, Hanauer S. Long-term results of oral cyclosporine in patients with severe ulcerative colitis: a double-blind, randomized, multi-center trial. Gastroenterology 1994;106(Suppl 2):A714 (Abtr)
73. Actis GC, Fada M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007;7:13 (available online)
74. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10(2):73-8
75. Message L. Boure& A. Laharie D, et al. Efficacy of intravenous cyclosporine in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005;29(3):231-5
76. Carbormel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in artacks of ulcerative colitis. Short-term and long-term responses. Dig Dis Sci 1996,41(12):2471-6
77. Fernandez-Banarez F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporinc in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91(12):2498-9
78. Van Gowum A, Schmit A, Adler M, et al. Short- and long-term Acacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 1997;60(3):197-200
79. Rayner C& McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18(3):303-8
80. Actis GC, Volpcs R, Rizzetto M. Oral microemulsion cydosporin to reduce steroids rapidly in chronic active ulcerative colitis. Eur J Gastrocritcrol Hepatol 1999;11(8):905-8
81. Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001;36(6):610-4
82. De Saussure P, Soravia C, Mord P, Hadengue A. Low-dose oral microemulsion cyclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005;22(3):203-8
83. Weber A. Fein F, Koch S, et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006;12(12):1131-5
84. Lawson MM, Thoma AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112
85. Gisbert JP, Gonzälez-Lama Y, Maté J. Systematic review: infliximab in ulcerative colitis. Aliment Pharmacol Ther 2007;25(1):19-37
86. Sands BE, Tremaine VJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7(2):83-8
87. Probert CS, Hearing SD, Schreiber S, et al. Inflixima in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52(7):998-1002
88. Lees CW, Heys D, Ho GT, et al.; On Behalf of the Scottish Society of Gastroenterology Group. A retrospective analysis of the efficacity and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26(3):411-9
89. Jacobovits SL, Jewell DP, Travis SPL Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007;26(9):1055-60
90. Chey WY, Hussain A. Ryan C, et al. Infliximab fbr refiwtory ulcerative colitis. Am J Gastroenterol 2001;96(8):2373-81
91. Järnerot A, Blomberg B, Bohr J, et al. Infliximab (Remicade) as rescue therapy in acute corticosteroid-resistant ulcerative colitis. Scand J Gastroenterol 2001;36(Suppi 233):08 (Abstr)
92. Kohn A. Prantera C. Pera A. et al. Anti-tumor necrosis fkctor-alpha (infliximab) in the treatment of severe ulcerative colitis: results of an open study on 13 patients. Dig Liver Dis 2002;34(9):626-30
93. Kohn A. Daperno M. Armuzzi A. et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26(5):747-56
94. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative colitis and Crohn's disease. Am J Gastroenterol 2001;96(3):773-5
95. Kambharn N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004;28(3):365-73
96. Hanauer SB. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2005;128(11):1358-9
97. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16(11):1167-71
98. Moskovitz D, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4(6):760-5. Erratum in Clin Gastroenterol Hepatol 2006;4(12):1551